Answers are grounded in this paper and cite their sources.
Immune-related adverse events (irAE) secondary to immune checkpoint inhibitors (ICI) have gastrointestinal (GI) manifestations, including gastritis, enteritis, and/or colitis. The long-term sequelae of ICI-associated GI toxicities (GI-irAE), particularly the development of disorders of gut-brain interaction, are not well known. We characterized the incidence of persistent GI symptoms after GI-irAE.
No takes yet. Share an insight, caveat, or question.
Varma et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: